First Cited
Last Cited

Articles citing This Document (Page 1 of 1)

Sodium-Glucose Cotransporter 2 Inhibitor Use Among Individuals AgeClinicoEconomics and Outcomes Research
Sodium-Glucose Co-transporter-2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Breakthrough in Improvement of Clinical Outcomes?European Medical Journal (Chelmsford, England)
The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World DataEuropean Endocrinology2018
A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-specific clinical success ratesJournal of Innovation and Entrepreneurship2020
Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetesJournal of Clinical Pharmacy and Therapeutics2020
SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathyFundamental and Clinical Pharmacology2020
Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard RatioClinical Drug Investigation2019
Management of Diabetes MellitusContemporary Cardiology2019
Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular diseaseRevista Portuguesa De Cardiologia2019
Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular diseaseRevista Portuguesa De Cardiologia (English Edition)2019
Leptin, cardiovascular diseases and type 2 diabetes mellitusActa Pharmacologica Sinica2018
Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-AnalysisDiabetes Therapy2018
Clinical assessment and treatment of diabetes in patients with chronic kidney diseaseRevista Clínica Espanõla2018
Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect ComparisonsDiabetes Therapy2018
SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REALJournal of the American College of Cardiology2018
Antihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current EvidencePharmacotherapy2018
Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived CardiomyocytesScientific Reports2018
Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategiesJournal of Diabetes2018
When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapyDiabetes/Metabolism Research and Reviews2018
Effect of glucose-lowering therapies on heart failureNature Reviews Cardiology2018
Clinical assessment and treatment of diabetes in patients with chronic kidney diseaseRevista Clinica Espanola2018
Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providersPostgraduate Medicine2018
Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysisCardiovascular Diabetology2017
Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitorsAnnals of Medicine2017
Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in PerspectiveClinical Therapeutics2017
Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trialsInternational Journal of Cardiology2017
Cardiovascular disease prevention strategies for type 2 diabetes mellitusExpert Opinion on Pharmacotherapy2017
Cardiovascular safety outcomes of new antidiabetic therapiesAmerican Journal of Health-System Pharmacy2017
Comparative Effectiveness for Glycemic Control in Older Adults with DiabetesCurrent Geriatrics Reports2017
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World UseDiabetes Therapy2017
The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populationsPostgraduate Medicine2017
A review on cardiovascular effects of newer hypoglycaemic medicationsAnnals of Medicine2017
Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney DiseaseJournal of the American Society of Nephrology: JASN2017
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)Diabetes Therapy2017
Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressureHypertension Research2017
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysisCardiovascular Diabetology2016
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysisDiabetes, Obesity and Metabolism2016
What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?Current Diabetes Reports2016
Long-term maintenance of efficacy of dapagliflozin in patients with type 2 diabetes mellitus and cardiovascular diseaseDiabetes, Obesity and Metabolism2016